Clinical Trials Sponsored by Xsira Pharmaceuticals

Total 19608 results

Alnylam Pharmaceuticals

Terminated

A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease

Amyloidosis | Leukocyte Chemotactic Factor 2 Amyloidosis

United States, Malaysia, United Kingdom, Mexico, Egypt, India
Hope Pharmaceuticals

Terminated

A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients (CALISTA)

Calciphylaxis

United States, Canada, United Kingdom
Quark Pharmaceuticals

Completed

QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant (ReGIFT)

Delayed Graft Function

United States, Spain, Canada, Australia, Netherlands, Germany, Belgium, France, Argentina, Brazil, Czechia
Braeburn Pharmaceuticals

Completed

Phase II Pharmacokinetics Study of CAM2038

Chronic Pain | Opioid Use Disorder

United States
Vanda Pharmaceuticals

Unknown

ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection

Coronavirus Infection

United States
Veloxis Pharmaceuticals

Terminated

LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis

Autoimmune Hepatitis

United States, Canada
Veloxis Pharmaceuticals

Completed

Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia

Dyslipidemia

United States
Alexion Pharmaceuticals

Terminated

Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment (EVIDENCE)

Atypical Hemolytic Uremic Syndrome

United States, Australia, Germany, United Kingdom
Regeneron Pharmaceuticals

Completed

Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers

Healthy Volunteer

Belgium
Syndax Pharmaceuticals

Terminated

A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma (ENGAGE-501)

Hodgkin's Lymphoma

United States
Ferring Pharmaceuticals

Completed

Cortiment® MMX Pharmacokinetic Study

Healthy

India
Bellicum Pharmaceuticals

Completed

Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer

Castrate Resistent Prostate Cancer

United States
Alexion Pharmaceuticals

Terminated

Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis

Myasthenia Gravis

United States, Canada, United Kingdom
Aerie Pharmaceuticals

Completed

Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Primary Open Angle Glaucoma or Ocular Hypertension

United States
Endo Pharmaceuticals

Completed

Durability and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women

Edematous Fibrosclerotic Panniculopathy

United States
Ferring Pharmaceuticals

Terminated

A Study to Investigate the Safety and Effect of the Study Drug (FE 204205) in Patients With Cirrhotic Portal Hypertension

Portal Hypertension

Spain
Ferring Pharmaceuticals

Completed

Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists. (ProComD)

Advanced Prostate Cancer

Germany
Alexion Pharmaceuticals

Terminated

A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

Neuromyelitis Optica | Neuromyelitis Optica Spectrum Disorder

Hong Kong, United States, United Kingdom, Croatia, Malaysia, Korea, Republic of, Turkey, Japan, Italy, Spain, Taiwan, Australia, Argentina, Thailand, Russian Federation, Czechia, Denmark, Germany
Ferring Pharmaceuticals

Completed

A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON

Prostate Cancer

United Kingdom, Netherlands, Ireland, Greece, France, Belgium, Denmark, Norway, Italy, Slovakia, Switzerland, Portugal, Finland, Hungary, Germany
Jazz Pharmaceuticals

Completed

"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"

Obstructive Sleep Apnea | Narcolepsy

United States, France, Canada, Germany, Netherlands, Finland
Regeneron Pharmaceuticals

Completed

Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men

Healthy Volunteers

New Zealand
Concert Pharmaceuticals

Completed

Food Effect Study of CTP-543 in Healthy Volunteers

Healthy

United States
Aerie Pharmaceuticals

Completed

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

Ocular Hypertension | Open Angle Glaucoma

United States
Regeneron Pharmaceuticals

Completed

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)

Neovascular Age-Related Macular Degeneration

United States
Alexion Pharmaceuticals

Completed

Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor

Stage V Chronic Kidney Disease

Australia, France, Italy, Spain, United Kingdom, Sweden
Regeneron Pharmaceuticals

Withdrawn

Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis

Sporadic Inclusion Body Myositis
Arrowhead Pharmaceuticals

Terminated

Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection

Hepatitis B

Korea, Republic of, Germany, China
Arrowhead Pharmaceuticals

Terminated

A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection

Hepatitis B

Korea, Republic of, Germany, China
Alexion Pharmaceuticals

Completed

Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)

Hypophosphatasia (HPP)

United States, Canada
Alexion Pharmaceuticals

Approved for marketing

Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)

Hypophosphatasia

United States, France
Alnylam Pharmaceuticals

Completed

The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant

ATTR Amyloidosis | Transthyretin (TTR)-Mediated Amyloidosis | Familial Amyloidotic Polyneuropathy (FAP) | Familial Amyloid Neuropathies

France, Germany, Portugal, United Kingdom, Sweden, Spain
Impel Pharmaceuticals

Completed

Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults

Migraine Headache

Australia
Alexion Pharmaceuticals

Completed

Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09

Hypophosphatasia | Bone Disease

United States
Alexion Pharmaceuticals

Completed

Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)

Hypophosphatasia

United States, Spain, Australia, United Kingdom, Italy, France, Canada, Germany, Japan, Russian Federation, Saudi Arabia, Turkey
Alexion Pharmaceuticals

Terminated

Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM

Multiple Myeloma | B-cell Chronic Lymphocytic Leukemia

United States
Ferring Pharmaceuticals

Completed

A Study to Measure Relationship Between Antimüllerian Hormone and Initial Dose of Menopur® (AME)

Infertility

France
Ferring Pharmaceuticals

Completed

Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix (DUO)

Prostate Cancer

France
Lexicon Pharmaceuticals

Completed

Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function

Healthy | Renal Impairment

United States
Vanda Pharmaceuticals

Unknown

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Relapsed or Refractory Hematologic Malignancies

United States
Prolong Pharmaceuticals

Terminated

Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia

Chemotherapy-induced Neutropenia

France, Netherlands
Rigel Pharmaceuticals

Completed

A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (FIT)

Immune Thrombocytopenic Purpura

United States, Australia, United Kingdom, Canada, Italy, Denmark, Hungary, Netherlands
Cumberland Pharmaceuticals

Completed

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus (ATTAIN2)

Bacterial Pneumonia

Israel
Cumberland Pharmaceuticals

Completed

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus (ATLAS1)

Staphylococcal Skin Infection

United States
Cumberland Pharmaceuticals

Completed

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus (ATTAIN1)

Bacterial Pneumonia

United States
Cumberland Pharmaceuticals

Completed

A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin

Kidney Diseases | End Stage Renal Disease

United States
Cumberland Pharmaceuticals

Completed

Telavancin Observational Use Registry (TOUR) (TOUR)

Complicated Skin and Skin Structure Infections | Hospital Acquired Bacterial Pneumonia | Ventilator Associated Bacterial Pneumonia | Gram Positive Infection

United States
Titan Pharmaceuticals

Completed

A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants (PRO-814)

Opioid Dependence
Alexion Pharmaceuticals

Terminated

A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease (GIGVHD)

Acute Graft-Versus-Host Disease | GIGVHD

United States, France
Titan Pharmaceuticals

Terminated

A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence (PRO-810)

Opioid Dependence

United States
Lexicon Pharmaceuticals

Completed

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Carcinoid Syndrome

United States

3

Subscribe